Gastric Cancer Clinical Trial
— SOURCEOfficial title:
Stimulating Evidence Based, Personalized and Tailored Information Provision to Improve Decision Making After Oesophagogastric CancEr Diagnosis - a Pragmatic Stepped Wedge Trial-
The overarching aim of the programme 'Stimulating evidence based, personalized and tailored information provision to improve decision making after oesophagogastric cancer diagnosis' (SOURCE) is to provide oesophagogastric cancer patients at all disease stages with evidence based and personalized information about survival, treatment-related side-effects and/or complications and health related quality of life, tailored to patients' specific information needs, to facilitate informed decision making about treatment and thereby optimize personal care and outcomes. For this purpose the Source tool and training were designed. The Source tool is a prediction model based website to be used by care givers for informing patients about the outcomes of treatment. The Source training for care givers is designed to learn care givers how to inform patients effectively, especially about the outcomes of treatment.
Status | Recruiting |
Enrollment | 126 |
Est. completion date | September 30, 2023 |
Est. primary completion date | September 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Health care providers: - Specialist, physician assistant or nurse practitioner in the field of oncology, oncological radiotherapy or oncological surgery who are used to discussing treatment and treatment outcome with patients - Informed consent for data collection - Three audiorecorded treatment information consultations with oesophageal or gastric cancer patients before the scheduled transition period (control measurements) - Three audiorecorded treatment information consultations with oesophageal or gastric cancer patients after the scheduled transition period (intervention measurements) and before the scheduled end date of the study Patients: - Age = 18 years - Histological or cytological proof of oesophageal or gastric cancer - Informed consent for trial data collection A treatment information consultation with a participating doctor to discuss either curative treatment, first line palliative treatment, and/or best supportive care. Exclusion Criteria: Health care providers: - Less than two control and/or intervention measurements Patients: - Cognitive impairment or insufficient understanding of the Dutch language - GIST and smallcell carcinomas. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Flevoziekenhuis | Almere | |
Netherlands | Academic Medical Center | Amsterdam | Noord Holland |
Netherlands | VUmc | Amsterdam | |
Netherlands | Radiotherapiegroep | Arnhem | |
Netherlands | Rijnstate | Arnhem | |
Netherlands | Catherina Ziekenhuis | Eindhoven | |
Netherlands | LUMC | Leiden | |
Netherlands | Maastro | Maastricht | |
Netherlands | Radboud UMC | Nijmegen | |
Netherlands | BVI | Tilburg | |
Netherlands | ETZ | Tilburg | |
Netherlands | UMC Utrecht | Utrecht |
Lead Sponsor | Collaborator |
---|---|
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Dutch Cancer Society |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Observed presence of Source tool measured with SOURCE observational scale | Health care providers' observed use of the Source tool Min. value: 0 Max. value:1 Value 0 means absence of Source tool in consultation, Value 1 means presence of Source tool in conversation | through study completion, an average of 1 year | |
Other | SOURCE evaluation questionnaire (tailor made evaluation questionnaire) | Health care providers' evaluation of the Source tool, training and e-learning Min value: 1 Max value: 10 Higher scores mean better evaluations | through study completion, an average of 1 year | |
Primary | SOURCE observational scale | The SOURCE observational scale is developed to primary answer the following question: Does the combination of the tool and the training improve observed (numerical) precision of information about treatment outcomes in clinical consultations? Min. value: 1 Max. value:4 Higher scores mean higher (numerical) precision | through study completion, an average of 1 year | |
Secondary | Continuing professional development (CPD) reaction Questionnaire | Health care providers' intention to inform patients about treatment outcomes using numbers (effect training only) | through study completion, an average of 1 year | |
Secondary | Patient Satisfaction Questionnaire (PSQ-5 patient and doctor version) | Patient and physician satisfaction with communication and decision making | 2 weeks | |
Secondary | Shared Decision Making Questionnaire (SDMQ-9) | Patient-reported shared decision making | 2 weeks | |
Secondary | Decisional Conflict Scale (DCS) | Patients' evaluation of the decision made | 2 weeks | |
Secondary | EORTC QLQ - INFO25 + tailor made items on treatment outcome information | Patients' evaluation and knowledge of the information provided by the health care provider | 2 weeks | |
Secondary | EORTC QLQ-C30 | Patients' health related quality of life, cancer specific | 3 months vs. baseline | |
Secondary | EORTC QLQ-OG25 | Patients' health related quality of life, gastro-intestinal cancer specific | 3 months vs. baseline | |
Secondary | Trust in the Oncologist Scale (TiOS-sf) | Patients' trust in the health care provider | 2 weeks | |
Secondary | State-Trait Anxiety Inventory (STAI) | Patients' anxiety | 2 weeks vs. baseline | |
Secondary | ((Mini-)Mental Adjustment to Cancer scale ((Mini-)MAC) | Patients' helplessness/hopelessness + fighting spirit | 2 weeks vs. baseline | |
Secondary | Duration of consultation in minutes (min.) | Consultation time | through study completion, an average of 1 year | |
Secondary | Health care providers' personalization of treatment outcome information measured with SOURCE observational scale | Frequency of explicitly personalizing treatment outcome information, based on audio tapes Min. value: 0 Max. value: endless Higher values mean more utterances of personalization | through study completion, an average of 1 year | |
Secondary | Health care providers' tailoring of treatment outcome information measured with SOURCE observational scale | Frequency of explicitly tailoring treatment outcome information, based on audio tapes Min. value: 0 Max. value: endless Higher values mean more utterances of tailoring | through study completion, an average of 1 year | |
Secondary | Health care providers' use of visualizations of treatment outcome information measured with SOURCE observational scale | Frequency of explicitly showing visualizations treatment outcome information, based on audio tapes Min. value: 0 Max. value: endless Higher values mean more utterances of showing visualizations | through study completion, an average of 1 year | |
Secondary | Health care providers' use of time frames when giving treatment outcome information measured with SOURCE observational scale | Presence of time frame when giving treatment outcome information, in utterances coded for the primary outcome Min. value: 0 Max. value: 1 Value 1 means time frame present, value 0 means time frame absent | through study completion, an average of 1 year | |
Secondary | Treatment outcome category of health care providers' treatment outcome information measured with SOURCE observational scale | Treatment outcome category of health care providers' treatment outcome information, in utterances coded for the primary outcome Values: Survival, Health-related Quality of Life, Side effects and complications, Progression of tumor Non-ordinal variable | through study completion, an average of 1 year | |
Secondary | Person initializing treatment outcome information measured with SOURCE observational scale | Person taking the initaitive for the health care provider's treatment outcome information, in utterances coded for the primary outcome Values: Health care provider, Patient Non-ordinal variable | through study completion, an average of 1 year | |
Secondary | Health care providers' (numerical) precision of treatment outcome information measured with SOURCE observational scale simulated patient consultations (effect intervention) | Health care providers' (numerical) precision of treatment outcome information measured in simulated patient consultations (effect intervention) Min. value: 1 Max. value:4 Higher scores mean higher (numerical) precision | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |